PROPYLTHIOURACIL
LOE ApproachingNDAORALTABLET
Approved
Jul 1947
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
PROPYLTHIOURACIL by Eli Lilly and Company is clinical pharmacology propylthiouracil inhibits the synthesis of thyroid hormones and thus is effective in the treatment of hyperthyroidism. First approved in 1947.
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Propylthiouracil is an oral small-molecule antithyroid agent that inhibits thyroid hormone synthesis and peripheral conversion of thyroxine to triiodothyronine, making it effective for hyperthyroidism and thyroid storm. It does not inactivate existing circulating hormones but prevents new hormone production. The drug has been a foundational treatment for thyroid disorders since 1947.
LOE Approaching
Legacy product approaching loss of exclusivity with moderate competitive pressure (30/100); expect defensive positioning and focus on retention strategies rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Propylthiouracil inhibits the synthesis of thyroid hormones and thus is effective in the treatment of hyperthyroidism. The drug does not inactivate existing thyroxine and triiodothyronine that are stored in the thyroid or circulating in the blood, nor does it interfere with…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on propylthiouracil offers limited growth trajectory but provides foundational experience in mature product management, defensive marketing, and healthcare stakeholder engagement. Career advancement typically requires transition to growth-stage assets or movement into endocrinology franchise leadership.
Product Manager
Worked on PROPYLTHIOURACIL at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.